The content on this site is intended for healthcare professionals only
Dr Pawlyn speaks with ecancer at EHA 23 about the suitability of ASCT from older myeloma patients.
She describes that, based on data patients selected for fitness and comorbitiies irrespective of age, the progression-free and overall survival of patients aged over 65 recommends ASCT as a treatment option.
Dr Pawlyn also spoke with ecancer at EHA in Madrid in 2017, here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
OncoAlert Round Up for August 25th - 31st, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
